MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,904K
Free Cash flow
-$16,147K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Impairment of long-lived assets
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Accrued expenses and other liabi...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-26,179
-18,891
-20,334
-19,595
Depreciation expense
216
338
347
346
Stock-based compensation expense
3,271
3,860
3,066
3,360
Net accretion of discounts on marketable securities
811
767
383
586
Impairment of long-lived assets
5,086
-
-
-
Unbilled accounts receivable
0
0
0
0
Prepaid expenses and other current assets
-2,242
179
-44
-44
Operating lease assets and liabilities
329
195
195
195
Other assets
-537
8
529
-3
Accounts payable
975
858
-1,105
946
Accrued expenses and other liabilities
-1,047
-3,766
2,291
1,487
Net cash used in operating activities
-16,039
-18,750
-16,798
-14,190
Purchases of marketable securities
24,216
155,337
26,137
17,293
Maturities of marketable securities
37,653
27,135
25,247
35,995
Proceeds received on pending sale of equipment held for sale
450
-
-
-
Purchases of property and equipment
108
8
159
90
Net cash (used in) provided by investing activities
13,779
-128,210
-1,049
18,612
Proceeds from issuance of common stock and pre-funded warrants in connection with public offerings, net of issuance costs
-
-
164,500
-
Payments of offering costs associated with the issuance of common stock and pre-funded warrants
0
333
-
-
Proceeds from issuance of common stock under benefit plans, net
356
21
3,802
64
Net cash provided by financing activities
356
-312
168,302
64
Net decrease in cash, cash equivalents and restricted cash
-1,904
-147,272
150,455
4,486
Cash, cash equivalents, and restricted cash, beginning of period
51,462
198,734
48,279
59,413
Cash, cash equivalents, and restricted cash, end of period
49,558
51,462
198,734
48,279
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$37,653K
(-74.90%↓ Y/Y)
Proceeds from issuance of
common stock under...
$356K
(18.27%↑ Y/Y)
Proceeds received on
pending sale of...
$450K
Net cash (used in)
provided by investing...
$13,779K
(4.74%↑ Y/Y)
Net cash provided by
financing activities
$356K
(18.27%↑ Y/Y)
Canceled cashflow
$24,324K
Net decrease in
cash, cash...
-$1,904K
(87.81%↑ Y/Y)
Canceled cashflow
$14,135K
Impairment of long-lived
assets
$5,086K
Stock-based compensation
expense
$3,271K
(-45.86%↓ Y/Y)
Prepaid expenses and
other current assets
-$2,242K
(-45.21%↓ Y/Y)
Accounts payable
$975K
(66.10%↑ Y/Y)
Other assets
-$537K
(-26950.00%↓ Y/Y)
Depreciation expense
$216K
(-69.01%↓ Y/Y)
Purchases of marketable
securities
$24,216K
(-82.30%↓ Y/Y)
Purchases of property and
equipment
$108K
(66.15%↑ Y/Y)
Net cash used in
operating activities
-$16,039K
(44.84%↑ Y/Y)
Canceled cashflow
$12,327K
Net loss
-$26,179K
(25.10%↑ Y/Y)
Accrued expenses and
other liabilities
-$1,047K
(61.97%↑ Y/Y)
Net accretion of
discounts on marketable...
$811K
(-59.12%↓ Y/Y)
Operating lease assets and
liabilities
$329K
(-6.80%↓ Y/Y)
Buy us a coffee
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)